Open-Label, Randomized Phase 1b Study of the Safety and Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years

Trial Profile

Open-Label, Randomized Phase 1b Study of the Safety and Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Influenza virus vaccine (Primary) ; VRC-FLUDNA063-00-VP (Primary) ; MF 59
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top